856676-33-0

Basic information

• Product Name: 8S-Cabergoline
• Synonyms: 8S-Cabergoline;(6aR,9S,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
• CAS NO: 856676-33-0
• Molecular Formula: C26H36N5O2
• Molecular Weight: 450.59634
• Product Categories: Neurochemicals, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 856676-33-0.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform, Methanol
• Stability: Not stable in methanol solution
• CAS DataBase Reference: 8S-Cabergoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8S-Cabergoline(856676-33-0)
• EPA Substance Registry System: 8S-Cabergoline(856676-33-0)

Safety Data

• Hazardous Substances Data: 856676-33-0(Hazardous Substances Data)

Usage

Uses

8S-Cabergoline is the S-isomer of Cabergoline (C050000), a dopamine D2-receptor agonist.

Upstream product

• 153415-36-2 6-Norcabergoline 
• 591-87-7 Allyl acetate 
• 85329-86-8 (6aR,9R,10aR)-7-allyl-N-[3-(dimethylamino)propyl]-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide 
• 109-90-0 ethyl isocyanate 
• 25952-53-8 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride 
• 81409-74-7 (6aR,9R,10aR)-7-allyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid 
• 1892-57-5 N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 
• 909724-71-6 C₃₂H₅₁N₅O₂Si 
• 109-55-7 1-amino-3-(dimethylamino)propane 
• 474397-68-7 tert-butyl (5R,8R,10R)-6-allyl-8-[[[3-(dimethylamino)propyl](phenoxycarbonyl)amino]carbonyl]ergoline-1-carboxylate 
• 474397-67-6 tert-butyl (5R,8R,10R)-6-allyl-8-[[[3-(dimethylamino)propyl]amino]carbonyl]ergoline-1-carboxylate 
• 72821-79-5 methyl (6aR,9R,10aR)-7-allyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylate 
• 474397-69-8 tert-butyl (5R,8R,10R)-6-allyl-8-[[[3-(dimethylamino)propyl][(ethylamino)carbonyl]amino]carbonyl]ergoline-1-carboxylate 

Relevant articles and documents

New and efficient process for the preperation of cabergoline and its intermediates

This invention relates to a new and efficient process for the production of dopamine agonists such as Cabergoline and the intermediates thereof.

PROCESS FOR THE PREPARATION OF CRYSTAL FORMS OF CABERGOLINE VIA NOVEL STABLE SOLVATES OF CABERGOLINE

The present invention relates to a process for producing cabergoline crystal forms. The process comprises preparation of the desired solvate of cabergoline from a solution of cabergoline in chloroaromatic solvents. Afterwards cabergoline crystal form is prepared by recovery from a solvate of cabergoline by drying or with desolvating in a solvent media.

Production of Cabergoline and Novel Polymorphic Form Thereof

The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.